Technology Transfer
from the EKFZ Ecosystem
Cancilico
MyeloAID is a cutting-edge AI-based technology designed to transform the diagnosis of hematological cancers. This tool aims to automate the morphological differentiation of bone marrow smears, a critical step in identifying various hematological disorders. It simplifies the traditional, time-consuming process of manually counting and classifying cells, delivering accurate results in minutes.
AI in Hematology
The AI in Hematology research group develops artificial intelligence (AI)-based models to enhance diagnosis, prognosis, and clinical decision-making in hematologic diseases. The research group leaders are CMO and CSO at Cancilico:
- Dr. med. Jan Moritz Middeke (CMO Cancilico)
- Dr. Jan-Niklas Eckard (CSO Cancilico)
Connected Consumables
Connected Consumables revolutionizes medical fluid consumables by integrating data connectivity, enabling safer and automated therapies. Unlike traditional consumables, their patented technology transforms simple components into smart systems, reducing errors, automating manual tasks, and easing the burden on medical staff. By bringing real-time data and digital control to medical procedures, this enhances efficiency, safety, and patient outcomes.
ConnCons GmbH was founded by Prof. Dr. med. Jochen Hampe, Scientific Speaker of the EKFZ for Digital Health and Director of the Department of Medicine I at the University Hospital of TU Dresden, and Dr. med. Nora Herzog, former Clinician Scientist at the EKFZ.
StratifAI
StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics. Its discovery platform, Polaris™, applies multimodal AI to clinical data, identifying prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers.
The company was founded in Berlin in 2023. Its founding members were Prof. Dr. med. Jakob N. Kather, Professor of Clinical Artificial Intelligence at the EKFZ for Digital Health, and Omar El Nahhas, a researcher at the Kather Lab.
Synagen
Synagen is transforming oncology through advanced AI technology and deep medical expertise. Their AI agents are designed to tackle complex challenges in healthcare. Their innovative solutions integrate seamlessly into clinical workflows, automating tasks, enhancing decision-making, and improving patient outcomes.
Synagen was founded in 2024 by Prof. Dr. med. Jakob Nikolas Kather and Dyke Ferber, researcher at the Kather Lab.
Related Publication
Dyke Ferber, Omar S. M. El Nahhas, Georg Wölflein, Isabella C. Wiest, Jan Clusmann, Marie-Elisabeth Leßmann, Sebastian Foersch, Jacqueline Lammert, Maximilian Tschochohei, Dirk Jäger, Manuel Salto-Tellez, Nikolaus Schultz, Daniel Truhn, Jakob Nikolas Kather: Development and validation of an autonomous artificial intelligence agent for clinical decision-making in oncology, Nature Cancer, 2025.